US011246840B2

(12) **United States Patent**
Enscore et al.

(10) **Patent No.: US 11,246,840 B2**
(45) **Date of Patent: Feb. 15, 2022**

(54) **ABUSE AND MISUSE DETERRENT TRANSDERMAL SYSTEMS**

(71) Applicant: **Nutriband, Inc.**, Orlando, FL (US)

(72) Inventors: **David James Enscore**, Johns Creek, GA (US); **Frank Tagliaferri**, Decatur, GA (US); **Steven Paul Damon**, Johns Creek, GA (US); **Alan Smith**, Atlanta, GA (US); **Jeffrey C. Gaulding**, Peachtree Corners, GA (US)

(73) Assignee: **NUTRIBAND, INC.**, Orlando, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/707,547**

(22) Filed: **Dec. 9, 2019**

(65) **Prior Publication Data**

US 2020/0113845 A1 Apr. 16, 2020

Related U.S. Application Data

(63) Continuation of application No. 16/190,749, filed on Nov. 14, 2018, which is a continuation of application No. 15/113,545, filed as application No. PCT/US2015/012196 on Jan. 21, 2015, now abandoned.

(60) Provisional application No. 62/083,620, filed on Nov. 24, 2014, provisional application No. 62/014,721, filed on Jun. 20, 2014, provisional application No. 62/014,723, filed on Jun. 20, 2014, provisional application No. 61/930,090, filed on Jan. 22, 2014, provisional application No. 61/930,104, filed on Jan. 22, 2014.

(51) **Int. Cl.**

A61K 9/70	(2006.01)
A61K 31/4458	(2006.01)
A61K 31/4468	(2006.01)
A61K 31/4535	(2006.01)
A61K 31/485	(2006.01)
A61K 31/167	(2006.01)
A61K 47/18	(2017.01)

(52) **U.S. Cl.**

CPC ***A61K 9/7084*** (2013.01); ***A61K 31/167*** (2013.01); ***A61K 31/4458*** (2013.01); ***A61K 31/4468*** (2013.01); ***A61K 31/4535*** (2013.01); ***A61K 31/485*** (2013.01); ***A61K 47/18*** (2013.01)

(58) **Field of Classification Search**

CPC A61K 9/7084; A61K 31/4535; A61K 31/4468; A61K 31/167; A61K 31/4458; A61K 31/485; A61K 47/18; A61K 9/70; A61P 25/30; A61P 25/04; C08F 214/26; C08F 214/18; A61F 13/02; A61L 15/44

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,799,157	B2 *	9/2010	Kato	C09J 7/403 156/87
2004/0109886	A1	6/2004	Rigby	
2004/0219195	A1	11/2004	Hart et al.	
2008/0020028	A1	1/2008	Shevchuk et al.	
2011/0245783	A1	10/2011	Stinchcomb et al.	
2011/0263613	A1 *	10/2011	Hendrickson	A61K 9/0009 514/256
2019/0076374	A1 *	3/2019	Enscore	A61K 31/4535

FOREIGN PATENT DOCUMENTS

WO	2004098567 A2	11/2004	
WO	2005081825 A2	9/2005	
WO	2008024408 A2	2/2008	
WO	WO-2008024408 A2 *	2/2008	A61K 9/7061
WO	WO-2008133982 A2 *	11/2008	A61K 36/534
WO	WO-2011106700 A1 *	9/2011	A61P 1/12

OTHER PUBLICATIONS

International Search Report dated Apr. 23, 2015 for International Application No. PCT/US2015/012196.
International Preliminary Report on Patentability dated Aug. 4, 2016 for corresponding International Application No. PCT/US2015/012196.
European Search Report dated Jul. 26, 2017 for corresponding EP Application No. 15740893.1.
Australian Examination Report dated Mar. 2, 2018 for corresponding AU Application No. 2015209466.
Russian Office Action dated Sep. 18, 2018 for corresponding RU Application No. 2016133853.
Japanese Office Action dated Sep. 21, 2018 for corresponding JP Application No. 2016-548240.
Mexican Office Action dated Jun. 18, 2019 for corresponding MX Application No. MX/a/2016/009493.
Russian Office Action dated Apr. 4, 2019 for corresponding RU Application No. 2016133853.
Chinese Office Action dated Jul. 26, 2019 for corresponding CN Application No. 201580015604.6.
Office Action dated Sep. 22, 2020 for corresponding Korean Application No. 10-2016-7022446 (includes English translation).

* cited by examiner

Primary Examiner — Quanglong N Truong
(74) *Attorney, Agent, or Firm* — Barnes & Thornburg LLP

(57) **ABSTRACT**

An abuse deterrent and misuse deterrent transdermal patch comprising aversive agents incorporated in the backing layer of the patch. The aversive agents can exhibit biphasic or sustained kinetics of release with an immediate portion released rapidly and an extended portion released in a prolonged manner when exposed to a dissolution medium. The prolonged aversive agent release provides deterrence against extraction of drug from fresh and used patches and serves to prevent accidental misuse of used patches by children. The abuse deterrent and misuse deterrent patch systems can be used for transdermal delivery of therapeutically active agents and particularly those drugs that are highly prone to abuse such as opiate and opioid analgesics and stimulants.

27 Claims, 5 Drawing Sheets